Tags : Novo Nordisk

PharmaShots’ Most Read News of 2019

The year 2019 has been a busy year for global pharma and biotech companies involved in M&A, option & licensing agreements and gaining approvals. Our team has compiled a list of 20 most read life sciences news on PharmaShots in 2019. 1. Celltrion Signed an Exclusive Co-Marketing Agreement with Juno in Australia Juno provided sales […]Read More

Novo Nordisk Signs a Five-Year Agreement with UVA Center for

Shots: UVA in collaboration with Novo Nordisk to co-develop virtual patient modeling for T2D patients. The collaboration will utilize UVA’s work and insights on patient simulation and data-driven models within diabetes and will initially have 15 employees with an expectation of increment The focus of the collaboration is developing ‘virtual innovation lab’ for gaining deep […]Read More

PharmaShots Weekly Snapshot (November 18-22, 2019)

1.  Lupin Launches Smart Device for Metered-Dose Inhalers to Support Treatment of Respiratory Diseases in India Published: Nov 22, 2019 | Tags: Lupin, Launches, Smart Device, Metered-Dose Inhalers, Support, Treatment, Respiratory Diseases, India 2. BioMarin Reports Submission of MAA to EMA for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A Published: Nov 21, 2019 | Tags: BioMarin, […]Read More

Novo Nordisk Collaborates with Dicerna to Discover and Develop RNAi

Shots: Dicerna to receive $175M up front, $50M equity investment, $75M for first three years of collaboration and up to $375.5M/ target as development, regulatory and commercialization milestones with royalties on product sales Both the companies will retain rights to co-develop and co-commercialize candidates and will explore up to 30 liver cell targets for which […]Read More

Insights+: The US FDA New Drug Approvals in September and

The US FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 35 new products so far in 2019. In 2018 FDA approved 59 novel products including 42 New Chemical Entities and 17 Biologics while breaking its last year’s record of approvals. However, there is a significant […]Read More

PharmaShots Weekly Snapshot (November 04-08, 2019)

1. Triumvira’s TAC01-CD19 Receives FDA’s Fast Track Designation for R/R Diffuse Large B-Cell Lymphoma Published: Nov 07, 2019 | Tags: Triumvira, TAC01-CD19, Receives, FDA, Fast Track Designation, R/R, Diffuse Large B-Cell Lymphoma 2. Janssen Reports Submission of MAA to EMA for its Investigational Ebola Vaccine Regimen to Prevent Ebola Virus Disease Published: Nov 07, 2019 | Tags: […]Read More

Novo Nordisk Signs an Exclusive Worldwide License Agreement with UBE

Shots: UBE to receive up front, development & commercial milestones and royalties on sales. Novo Nordisk to get exclusive WW license to UBE’s preclinical asset UD-014 and will be responsible for development, manufacturing and commercialization of UD-014 The collaboration will widen Novo Nordisk’s presence and investment in NASH and will provide more treatment options to […]Read More

PharmaShots Weekly Snapshot (October 21-25, 2019)

1. Urology San Antonio Collaborates with Anixa Biosciences on Ccheck Prostate Cancer Study Published: Oct 25, 2019 | Tags: Urology San Antonio, Collaborates, Anixa Biosciences, Ccheck, Prostate Cancer Study 2. NHS England Signs an Agreement with Vertex to Access All Licensed Cystic Fibrosis Therapies Published: Oct 24, 2019 | Tags: NHS England, Signs, Agreement, Vertex, Access, Licensed, […]Read More